• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Japan approves expanded reimbursement coverage for Abbott’s FreeStyle Libre CGM

March 24, 2022 By Sean Whooley

Abbott FreeStyle Libre CGM
Abbott’s FreeStyle Libre CGM [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced today that it received expanded reimbursement coverage in Japan for the FreeStyle Libre system.

Japan’s Ministry of Health, Labour and Welfare approved the expansion for the continuous glucose monitoring (CGM) system to include all people with diabetes who use insulin at least once per day.

Abbott Park, Illinois-based Abbott said the expanded coverage enables more people with diabetes to access the glucose data needed for managing their condition without the need for the routine fingersticks commonly associated with traditional blood glucose monitoring.

The reimbursement expansion in Japan takes effect on April 1, 2022. The company said the expansion was granted based on FreeStyle Libre’s overall value proposition, which included ease of use and scientific evidence of the clinical benefits associated with using FreeStyle Libre.

“The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre system with access and affordability in mind from the very beginning,” Jared Watkin, SVP of Abbott’s diabetes business, said in a news release. “FreeStyle Libre systems provide a complete and comprehensive glucose picture without the need for routine fingersticks. The technology helps enable behavior change, which ultimately helps people live better, fuller lives.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Reimbursement

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS